We analysed hundreds of nominations for the Nobel Prize in Physiology or Medicine for the period 1901-66 to gain insight into how Nobel committees judged scientific research as worthy of this ultimate accolade.
Nomination letters become public 50 years after the award. Some simply highlight their nominees' lifetime achievements and portray individuals as worldleading scholars in their field. The (unsuccessful) nomination letters for antiseptics pioneer Joseph Lister, for instance, stated that he had "done more for the good of humanity than any other [living] member of the medical profession".
Others focus on discoveries that could open up new research areas. The sponsors of physician Charles Huggins, for example, argued that his "visionary" work meant that cancer was no longer perceived as an insurmountable problem. Huggins was awarded the Nobel in 1966 for his work on the hormonal treatment of prostate cancer.
The outcome of the nominations we studied
Social justice in the Belt and Road plan
Guo Huadong outlines proposals to share big data on Earth observations across Asia, the Middle East and East Africa to ensure that China's Belt and Road Initiative (BRI) will contribute to sustainability (Nature 554, 25-27; 2018) . Sustainability also includes issues of social justice and so, on the basis of the United Nations Sustainable Development Goals, the BRI should include respect for human rights as well, so that everyone benefits.
In our view, the BRI could achieve this social sustainability by including bottom-up participation in all countries involved. China should do more to encourage European countries to sign up to the BRI and enhance the balance of views.
Transnational 'digital democracy' should reach beyond the exchange of goods, services and investments by empowering citizens, increasing opportunities for all and promoting peace (D. Helbing and P. Seele Nature 549, 458; 2017 Peer-review panels can be a wolf pack I agree with Gemma Derrick that grant-review panels should be more collaborative so that they benefit from all the expertise around the table (Nature 554, 7; 2018). What I've seen of how these panels are conducted brings to mind a predatory wolf pack, rather than the tug of war between alliances that she describes.
My experience over the years is that one or two internationally eminent alpha personalities lead the room with their views on the applicant's kudos and calibre and whether this is sufficient to warrant consideration. The group dynamic then shifts palpably as panellists fall into line to concur. Individuals who would normally review work in their field confidently and independently start to act as a mob.
This unproductive behaviour would be alleviated if panels required all members to make their own initial assessment of proposals ahead of the meeting and to submit a voice message summarizing their appraisal to the chair. Grounding ME/CFS therapies in science I welcome the suggestion that patients with myalgic encephalomyelitis (also known as chronic fatigue syndrome; ME/CFS) should not be dismissed (M. Sharpe et al. Nature 554, 31; 2018) . However, as someone who has been diagnosed with ME/CFS for 25 years, I contend that this argument should not be misused to perpetuate ineffective therapies that could raise false hopes and might amount to mistreatment.
As you point out (Nature 553, 14-17; 2018), the PACE trial authors (including two co-authors of Sharpe et al. in Nature) and others promote a form of cognitive behavioural therapy that assumes ME/CFS symptoms can be reversed by teaching people to think differently, and a prescribed form of graded exercise that might be harmful. Sharpe and colleagues urge readers not to reject scientific evidence that supports the use of such approaches. However, the Cochrane Reviews they cite rely on the results of the disputed PACE trial and several other studies that have similar methodological flaws. It is also notable that Sharpe and colleagues concluded: "There was little evidence of differences in outcomes between the randomised treatment groups at long-term follow-up" (see M. Sharpe et al. Lancet Psychiatry 2, 1067-1074; 2015) .
The returns might be some way off, but the latest moves to pursue the growing evidence that ME/CFS symptoms are rooted in pathology is the proper approach (see, for example, go.nature. com/2fimftx). Robert Saunders Balcombe, West Sussex, UK. rhsaunders@gmail.com 
